367 related articles for article (PubMed ID: 28789916)
21. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome.
Schneider HE; Steinmetz M; Krause U; Kriebel T; Ruschewski W; Paul T
Clin Res Cardiol; 2013 Jan; 102(1):33-42. PubMed ID: 22821214
[TBL] [Abstract][Full Text] [Related]
22. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
[TBL] [Abstract][Full Text] [Related]
23. Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies.
Bergeman AT; Wilde AAM; van der Werf C
Card Electrophysiol Clin; 2023 Sep; 15(3):293-305. PubMed ID: 37558300
[TBL] [Abstract][Full Text] [Related]
24. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
Kohli U; Aziz Z; Beaser AD; Nayak HM
Pacing Clin Electrophysiol; 2019 Aug; 42(8):1146-1154. PubMed ID: 30912151
[TBL] [Abstract][Full Text] [Related]
25. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
[TBL] [Abstract][Full Text] [Related]
26. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
[TBL] [Abstract][Full Text] [Related]
27. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome.
Roston TM; Wei J; Guo W; Li Y; Zhong X; Wang R; Estillore JP; Peltenburg PJ; Noguer FRI; Till J; Eckhardt LL; Orland KM; Hamilton R; LaPage MJ; Krahn AD; Tadros R; Vinocur JM; Kallas D; Franciosi S; Roberts JD; Wilde AAM; Jensen HK; Sanatani S; Chen SRW
JAMA Cardiol; 2022 Jan; 7(1):84-92. PubMed ID: 34730774
[TBL] [Abstract][Full Text] [Related]
28. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
Pflaumer A; Davis AM
Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
[TBL] [Abstract][Full Text] [Related]
29. Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.
Wangüemert-Pérez F; Ruiz-Hernández PM; Campuzano O; Caballero-Dorta E; Bosch C; Brugada J; Brugada R
Minerva Cardioangiol; 2014 Aug; 62(4):363-6. PubMed ID: 25012103
[No Abstract] [Full Text] [Related]
30. Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.
Hong RA; Rivera KK; Jittirat A; Choi JJ
Pacing Clin Electrophysiol; 2012 Jul; 35(7):794-7. PubMed ID: 22553997
[TBL] [Abstract][Full Text] [Related]
31. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.
van der Werf C; Nederend I; Hofman N; van Geloven N; Ebink C; Frohn-Mulder IM; Alings AM; Bosker HA; Bracke FA; van den Heuvel F; Waalewijn RA; Bikker H; van Tintelen JP; Bhuiyan ZA; van den Berg MP; Wilde AA
Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):748-56. PubMed ID: 22787013
[TBL] [Abstract][Full Text] [Related]
32. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia.
Marai I; Khoury A; Suleiman M; Gepstein L; Blich M; Lorber A; Boulos M
Am J Cardiol; 2012 Jul; 110(1):72-6. PubMed ID: 22481011
[TBL] [Abstract][Full Text] [Related]
33. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
Wangüemert F; Bosch Calero C; Pérez C; Campuzano O; Beltran-Alvarez P; Scornik FS; Iglesias A; Berne P; Allegue C; Ruiz Hernandez PM; Brugada J; Pérez GJ; Brugada R
Heart Rhythm; 2015 Jul; 12(7):1636-43. PubMed ID: 25814417
[TBL] [Abstract][Full Text] [Related]
34. A novel mutation in the RYR2 gene leading to catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation: dose-dependent arrhythmia-event suppression by β-blocker therapy.
Kazemian P; Gollob MH; Pantano A; Oudit GY
Can J Cardiol; 2011; 27(6):870.e7-10. PubMed ID: 21652165
[TBL] [Abstract][Full Text] [Related]
35. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
Leren IS; Saberniak J; Majid E; Haland TF; Edvardsen T; Haugaa KH
Heart Rhythm; 2016 Feb; 13(2):433-40. PubMed ID: 26432584
[TBL] [Abstract][Full Text] [Related]
36. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Ruan Y; Priori SG
Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
Haugaa KH; Leren IS; Berge KE; Bathen J; Loennechen JP; Anfinsen OG; Früh A; Edvardsen T; Kongsgård E; Leren TP; Amlie JP
Europace; 2010 Mar; 12(3):417-23. PubMed ID: 20106799
[TBL] [Abstract][Full Text] [Related]
38. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest.
van der Werf C; Lieve KV; Bos JM; Lane CM; Denjoy I; Roses-Noguer F; Aiba T; Wada Y; Ingles J; Leren IS; Rudic B; Schwartz PJ; Maltret A; Sacher F; Skinner JR; Krahn AD; Roston TM; Tfelt-Hansen J; Swan H; Robyns T; Ohno S; Roberts JD; van den Berg MP; Kammeraad JA; Probst V; Kannankeril PJ; Blom NA; Behr ER; Borggrefe M; Haugaa KH; Semsarian C; Horie M; Shimizu W; Till JA; Leenhardt A; Ackerman MJ; Wilde AA
Eur Heart J; 2019 Sep; 40(35):2953-2961. PubMed ID: 31145795
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers.
Mazzanti A; Kukavica D; Trancuccio A; Memmi M; Bloise R; Gambelli P; Marino M; Ortíz-Genga M; Morini M; Monteforte N; Giordano U; Keegan R; Tomasi L; Anastasakis A; Davis AM; Shimizu W; Blom NA; Santiago DJ; Napolitano C; Monserrat L; Priori SG
JAMA Cardiol; 2022 May; 7(5):504-512. PubMed ID: 35353122
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.
van der Werf C; Zwinderman AH; Wilde AA
Europace; 2012 Feb; 14(2):175-83. PubMed ID: 21893508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
